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Background: Protease inhibitors (PI) including boceprevir, telaprevir and simeprevir have revolutionised
HCV genotype 1 treatment since their introduction. A number of pre-treatment resistance associated
aminoacidvariants (RAVs)andpolymorphismshavebeenassociatedwith reducedresponse to treatment.
Objectives: We measured the prevalence of RAVs/polymorphisms in a PI treatment-naïve HCV genotype
1 Scottish cohort using Sanger sequencing.
Study design: Chronically infected, treatment-naïve, HCV genotype 1 patients (n=146) attending NHS
Greater Glasgow and Clyde clinics were investigated for RAVs/polymorphisms to the PIs boceprevir,
telaprevir and simeprevir. The NS3/4A region was ampliﬁed by nested polymerase chain reaction. The
1.4 kb ampliﬁed product was sequenced using an ABI 3710XL DNA sequencer. Sequence analysis was
performed using web-based ReCall (beta 2.10). Amino acid positions 36, 41, 43, 54, 55, 80, 109, 122, 155,
156, 168 and 170 were analysed for RAVs/polymorphisms.
Results: Overall, 23.29% (34/146) of patients had an RAV or polymorphism detected. Overall, 13.69%
(20/146) of patients had HCV virus that contained the Q8 K polymorphism. Other RAVs detected were:
V36 M 0.70% (1/146), V36L 0.70% (1/146), T54S 6.85% (10/146), V55A 3.42% (5/146) and V/I170A 0.68%
(1/146). Four patients had dual combinations of mutations (T54S+V36L; T54S+V55A and 2 patients with
T54S+Q80K).
Conclusions: Q80K was the most prevalent baseline polymorphism detected in the Scottish cohort.
Simeprevir treatment is not recommended in patients infected with the Q80K genotype 1a variant. This
highlights the need for baseline sequencing prior to administration of this drug in this population.
Crown Copyright © 2015 Published by Elsevier B.V. This is an open access article under the CC BY
license (http://creativecommons.org/licenses/by/4.0/).
1. Background
Traditionally genotype 1HCV infections have been the hard-
est to treat with sustained virological response (SVR) rates to the
standard of care treatment of ribavirin (RBV) co-administered with
pegylated-interferon alpha (IFN) in the region of 42–50% [1,2]. The
development of non-structural protein 3 (NS3) protease inhibitors
(PIs) including telaprevir, boceprevir and simeprevir, has substan-
tially improved outcome in these patients with SVR rates now
approaching 80% in both treatment-naive patients and relapsers
[3–6]. Newer PI based IFN-free regimens show even greater poten-
tial and lower toxicity. For example, the combination of simeprevir
and the NS5B polymerase inhibitor sofosbuvir increased the SVR
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to over 90% in genotype 1 patients [7]. NS5A inhibitors daclatasvir
or ledipasvir when used with sofosbuvir have also generated SVR
rates >90% [8,9]. Further breakthroughs are expected as other com-
binations of antivirals become available which promise to offer
improvements in SVR, shortened duration of treatment and lower
pill burden.
A number of pre-treatment resistance associated amino acid
variants (RAVs) within NS3 are associated with reduced response
to PI–IFN regimens. For example, RAVs at position 156 (A156T/V)
and R155K have been shown to reduce the effectiveness of all cur-
rent PIs [10–13]. Substitutions at theD168 locus (D168T/Y/H/A/V/I)
result in high-level resistance to simeprevir (>300 fold) and the
other 2nd generation PIs only [13–15]. Resistance polymorphisms
Q80K or R have been shown to negate the beneﬁt of adding
simeprevir to pegylated IFN and RBV [16] and, for this reason, it
is recommended in the license that patients infected with geno-
type 1a HCV who have evidence of Q80K/R mutations are not
http://dx.doi.org/10.1016/j.jcv.2015.02.005
1386-6532/Crown Copyright © 2015 Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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considered for treatment with simeprevir. RAVs at amino acid pos-
itions 36, 41, 43, 54, 55, 109, 122 and 170 have also been reported
[11,13,14,17,18]. However, their signiﬁcance is currently uncertain
with most reports suggesting that they only have a minor effect on
overall SVR rates. Only a few studies have examined the prevalence
of the aforementioned RAVs at baseline [19–23]. Knowing their fre-
quency, can be used to plan treatment policies and will determine
the usefulness of baseline testing prior to treatment.
2. Objectives
We measured the prevalence of natural resistance polymor-
phisms in a protease inhibitor treatment-naïve HCV genotype 1
Scottish cohort using Sanger sequencing.
3. Study design
3.1. Patients
Stored plasma samples, taken between August 2013 and March
2014 for 146 chronically infected HCV genotype 1 patients attend-
ing clinics within NHS Greater Glasgow & Clyde, were used in this
study. The patients consisted of 141 treatment naïve patients and 5
treatment relapsers who had previously been treated with pegy-
lated IFN and RBV. The majority of the patients (n=140) were
subtype 1a and six subtype 1b. All patients had a detectable HCV
RNA tested by Abbott RealTime HCV (detection limit 12 IU/ml).
3.2. RNA extraction
RNA was extracted using the NucliSens easyMag (BioMerieux).
Using the on-board lysis protocol, 1000l of sample was eluted to
60l.
3.3. PCR ampliﬁcation and sequencing procedure
The NS3/4A region was ampliﬁed by nested polymerase chain
reaction (PCR) using a method and primers supplied by Dr Richard
Harrigan (British Columbia Centre for Excellence in HIV/AIDS).
The 1st round primer sequences were: 5′ TTCAGCCTGGACC-
CTACCTTTACCAT 3′ (position 4731–4756), 5′ ATGGAGATCAAG-
GTCATCACGTGGGG 3′ (position 3276–3301) and 5′ GTGGCCG-
TAGAGCCTGTCGTCTTC 3′ (position 3246–3269). The 2nd round
primer sequences were: 5′ GACTTCGACTCTGTGATAGACTGCAAC
3′ (position 4680–4706), 5′ TCAAGGTCATCACGTGGGGGGCGGA
3′ (position 3283–3307) and 5′ TACCGGCGACTTCGACTCGGT-
GAT 3′ (position 4673–4696). The 1st round PCR ampliﬁcation
was carried out using a Qiagen OneStep RT-PCR kit and the
2nd round with the Expand High Fidelity PCR system (Roche
Diagnostics GmbH). Sanger sequencing was performed on the
ABI 3710XL DNA sequencer with Big Dye v3.1. The 1.4 kb
sequence was analysed using web-based ReCall beta v2.10
(http://pssm.cfenet.ubc.ca/home/index). Using the amino acid fea-
ture on ReCall, the following amino acid positions were analysed:
36, 41, 43, 54, 55, 80, 109, 122, 155, 156, 168 and 170.
4. Results
There was no evidence of RAVs at position 155, 156 and 168
in any of the sequences analysed (Table 1 ). The polymorphism
Q80K was found in 13.69% (20/146) of patients sequenced. Other
RAVswere found at the following frequencies: 0.70% (1/146)V36M,
0.70% (1/146) V36L, 6.85% (10/146) T54S 3.42% (5/146) V55A and
0.68% (1/146) V/I170A. Four patients were identiﬁed as having
dual combinations of mutations (T54S+V36L; T54S+V55A and 2
patients with T54S+Q80K).
5. Discussion
This study analysed sequences from the NS3/4A serine pro-
tease region of 146 genotype 1 patients (140 were genotype 1a
and 6 were genotype 1b). The low level of subtype 1b patients
in this study is a reﬂection of the Scottish population, where
subtype 1a predominates. This is also a reﬂection of the UK pop-
ulation as a whole [24]. Overall 23.29% of patients tested had NS3
RAVs/polymorphisms without prior exposure to PIs. No high-level
resistant RAVs were detected at positions 155, 156 or 168. Other
prevalence studies in treatment-naive patients have shown that
these three key resistancemutations either occur at a very low level
(<0.9%) or not at all [21.25,26]. Themajority of patients had the nat-
urally occurring polymorphism Q80K (13.69%). The prevalence of
Q80K in the Scottish cohort is similar to that found in other Euro-
pean studies; France 10.5%; Italy 10.1%; London 16% and Sweden
5.7% [20,22,23,27]. Q80K prevalence in the USA has been reported
at higher prevalence levels of 37% and 47% [19,21]. Mutational dif-
ferences between genotype 1 subtypes and clades within subtype
1 may reﬂect differences seen between American and European
patients [19,28,29]. Studies have alsohighlighted thatQ80K ismore
likely to occur in patients with subtype 1a HCV than subtype 1b
[20,21].
The V36L/M, T54S, V55A andV/I170Amutations detected in this
study are low level resistance RAVs that have little effect on SVR
rates in patients treated with triple therapy [21,30]. These inde-
terminate or low level RAVs have been reported at a prevalence of
between 0.2% and 11% [20,21,25–27]. The mutations V36M, V36L
and V/I170A do not appear to be detrimental to viral ﬁtness com-
pared with high level resistance mutations and may explain the
presence of these mutations within untreated populations [10,31].
In this study, T54S was found at a prevalence of 7.53% within the
Scottish cohort. This mutation confers low level resistance to both
boceprevir and telprevir but not simeprevir [13,32,33]. T54S has
been identiﬁed in 7.5% treatment-naive patients in Sweden and
2.8% in Italy [20,22].
In this study four (2.74%) subtype 1a patients were found to
have RAV combinations, which all contained T54S with another
mutation (T54S+V36L; T54S+V55A and T54S+Q80K). Bae et al.
[19] found that the combination of T54S and Q80K did not increase
drug resistance to simeprevir but did reduce resistance to bocepre-
vir and teleprevir when compared to the single mutation T54S (<3
fold–5 fold). The combinationofV36L+T54Shasbeen reportedpre-
viously [20]. It is unclear if this combination substantially increases
resistance to PIs but the mutational combination of V36M+T54S
increases viral ﬁtness compared to a virus with T54S only [18].
CombinationRAVatpositions54and55havebeen shown to reduce
response to triple therapy containing boceprevir [34].
This study examined the frequency of NS3 variants detected by
Sanger sequencing. Sanger sequencing will only detect these vari-
ants at a frequency of >20%. Next generation sequencing (NGS) can
detect lower frequency variants by measuring population variants
that occur at <1% [35]. As a result studiesusingNGSwill likelydetect
RAVs at an increased frequency. NGS studies of the NS3 region in
treatment-naive patients, have again identiﬁed Q80K as the most
prevalent baseline mutation with ∼42% harbouring this polymor-
phism [36,37].
Currently, European guidelines have six suggested treatment
options for genotype 1 patients with simeprevir recommended
within two of these treatment protocols [38]. This study conﬁrms
that high-level resistance RAVs 155, 156 and 168 are rare within
the treatment-naïve population in the West of Scotland. However,
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Table 1
NS3/4A mutations detected in a group of PI treatment naive patients. Mutation list was adapted from Lenz et al. [13]; Leggewie et al. [27]; Forns et al. [6]; Povada et al. [29];
Schneider and Sarrazin [41].
Amino acid position Mutation Prevalence in
Scottish cohort
(n=146)
Drug
V36 M
L
G
1/146 (0.68%)
1/146 (0.68%)
0.00%
Boceprevir,
telaprevir,
simeprevir
Q41 R 0.00%
F43 S
I
V
0.00%
0.00%
0.00%
Simeprevir
T54 S
A
10/146 (6.85%)
0.00%
Boceprevir,
telaprevir,
simeprevir
V55 A 5/146 (3.42%)a Boceprevir,
telaprevir
Q80 K
R
20/146 (13.69%)
0.00%
Simeprevir
R109 K 0.00% Boceprevir
S122 R 0.00% Simeprevir
R155 K
T
0.00%
0.00%
Boceprevir,
telaprevir,
simeprevir
A156 S
T
V
0.00%
0.00%
0.00%
Boceprevir,
telaprevir,
simeprevir
D168 A
V
I
T
H
E
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
Simeprevir
V/I170 A 1/146 (0.68%) Boceprevir,
telaprevir
a 1/5 of the sequences was a wild type/resistant mixture (V55A/V).
Q80K is common (13.69%) and baseline sequencing prior to therapy
should be considered when considering simeprevir/IFN treatment
in genotype 1a patients. It is possible that such testing will only
be a temporary measure since newer dual therapies may largely
overcome the negative effect of the Q80K mutation [39,40].
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